Quarterly report pursuant to Section 13 or 15(d)

PREPAID EXPENSES AND OTHER CURRENT ASSETS

v3.24.1.1.u2
PREPAID EXPENSES AND OTHER CURRENT ASSETS
 3 Months Ended
Mar. 31, 2024
Prepaid Expenses And Other Current Assets  
PREPAID EXPENSES AND OTHER CURRENT ASSETS

NOTE 5. PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

The Company’s prepaid expenses and other current assets consist of the following:

 

    March 31, 2024     December 31, 2023  
Other receivables   £ 51,826     £ 51,584  
VAT owed to the Company     66,957       135,642  
Prepaid clinical trial costs     307,519       307,519  
Deferred clinical trial testing costs     1,177,500       1,177,500  
Other prepayments     463,688       522,480  
Total   £ 2,067,490     £ 2,194,725  

 

The fair value of trade and other receivables are not materially different to the book value.